Clinical Trial Update: A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of Investigational Product (VM-001) in Patients With Graft-versus-host Disease(GvHD) [Phase 1, Phase 2]

View source ↗

Summary

A phase I/IIa open-label trial evaluating safety, tolerability, and pharmacodynamics of VM-001 in patients with graft-versus-host disease (GvHD). Status not spe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• VM-001

Snippet

Sponsor: ViGenCell Inc. | Conditions: Graft Versus Host Disease | Phase 1, Phase 2 | Status: UNKNOWN